WallStreet Research(TM) Announces Availability of Updated Corporate Profile Coverage On Pressure BioSciences, Inc. (OTCQB: PBIO)
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / WallStreet Research™, a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated corporate profile coverage on Pressure BioSciences, Inc. (PBIO). WallStreet Research™ is ranked number one on the Google, Yahoo, and Bing search engines in both and small and microcap research. An updated analyst Corporate Profile Report, together with additional information about WallStreet Research™, is available at the www.WallStreetResearch.org website.
The Corporate Profile highlights the recent accomplishments and growth plans under the guidance of the company's management that includes CEO Mr. Richard T. Schumacher, the founder of the company. Pressure BioSciences, Inc. recently signed an exclusive, two-year co-marketing agreement with a large strategic partner named SCIEX, which offers tremendous potential for revenue growth. SCIEX is a global leader in life sciences analytical technologies and a wholly owned subsidiary of the Danaher Corporation (NYSE:DHR).
Mr. Alan Stone, Managing Director of WallStreet Research™, added: "WSR is very impressed with Pressure BioSciences' management; current business strategy; recent milestone accomplishments, including the release of several enhanced products; successful close of over $6.3M in recent PIPE financing; retirement of all outstanding floorless convertible notes, to reduce dilution; and strong product endorsements from worldwide key opinion leaders. The Company significantly improved its financial results and balance sheet during FY 2015 and the three month period ended March 31, 2016, including 26% reported revenue growth for the first quarter. We strongly believe that at current levels PBIO is highly undervalued, and may soon surpass its 52-week high. The PBIO shares have shown strong momentum, significantly increased volume and solid price gains since the last report. WSR has followed the company for several years prior to initiating corporate profile coverage in November, 2015."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The Company's products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, the Company has installed over 275 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. The Company's primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use their products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.